Capping Off The Rebate Debate: Will 2019 Price Push End With Co-Pay Cap?
The pharmaceutical industry and its strongest critics have long agreed on one thing: Medicare Part D would be improved if there was a cap on spending by beneficiaries. Now, there is an unlikely path that may make it surprisingly easy to get it done.
You may also be interested in...
A series of abstracts highlight the impact of the ACA and Medicaid expansion on ovarian cancer diagnosis, racial disparities in time to treatment and the impact of insurance type on myeloma survival.
Biopharma manufacturers might not like the cost offsets that would cover the out-of-pocket maximum for patients in Medicare's drug program; committees seek comment on range of issues.
HHS downplays latest attempt to predict “complex behavior changes to a broken system.”